加载中
HKSEHealthcareMedical - Pharmaceuticals
最新数据
HK$5.665
−HK$0.14 · -2.41%
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
最新数据
HK$5.665
−HK$0.14 · -2.41%
盘中时间采用HKT。市场数据可能有所延迟。
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
日内区间
当前HK$5.665
52周区间
当前HK$5.665
盘中时间采用HKT。市场数据可能有所延迟。
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
日内区间
当前HK$5.665
52周区间
当前HK$5.665
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（CNY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 87.55亿 CNY | 84.66亿 CNY | 81.01亿 CNY | 75.03亿 CNY | 65.6亿 CNY |
| 销货成本 | 71.1亿 CNY | 64.25亿 CNY | 57.79亿 CNY | 54.66亿 CNY | 47.86亿 CNY |
| 毛利 | 16.45亿 CNY | 20.42亿 CNY | 23.21亿 CNY | 20.37亿 CNY | 17.74亿 CNY |
| 研究与开发 | 4.4亿 CNY | 4.13亿 CNY | 4.19亿 CNY | 3.46亿 CNY | 3.41亿 CNY |
| 销售、一般及管理费用 | 3.41亿 CNY | 6.08亿 CNY | 12.98亿 CNY | 8.15亿 CNY | 6.89亿 CNY |
| 营业费用 | 12.28亿 CNY | 15.07亿 CNY | 17.87亿 CNY | 14.94亿 CNY | 12.75亿 CNY |
| 利息收入 | 748.65万 CNY | 1112.55万 CNY | 937.68万 CNY | 1046.2万 CNY | 877.63万 CNY |
| 利息支出 | 4333.2万 CNY | 3973.93万 CNY | 4114.86万 CNY | 4970.69万 CNY | 5310.34万 CNY |
| 折旧和摊销 | 5.88亿 CNY | 5.41亿 CNY | 5.17亿 CNY | 4.85亿 CNY | 4.34亿 CNY |
| 营业利润 | 3.64亿 CNY | 5.34亿 CNY | 5.35亿 CNY | 4.77亿 CNY | 4.26亿 CNY |
| 净利润 | 2.9亿 CNY | 4.7亿 CNY | 4.97亿 CNY | 4.11亿 CNY | 3.49亿 CNY |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
年度分割调整后的每股现金分配。
HK$0.2731
2025年（完整年度）+51.7% 自从 2021
2026年（部分年度）：HK$0.1725
HK$0.1801
2,021
HK$0.1758
2,022
HK$0.2189
2,023
HK$0.3014
2,024
HK$0.2731
2,025
HK$0.1725
2,026*
* 在现有股息历史记录中，该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年7月10日 | HK$0.1725Annual | 2026年7月13日 | 2026年7月31日 |
股息 | 2025年6月27日 | HK$0.2731Semi-Annual | 2025年6月30日 | 2025年7月18日 |
股息 | 2024年9月4日 | HK$0.0273Semi-Annual | 2024年9月5日 | 2024年9月27日 |
股息 | 2024年7月10日 | HK$0.2741Semi-Annual | 2024年7月11日 | 2024年7月30日 |
股息 | 2023年7月7日 | HK$0.2189Annual | 2023年7月10日 | 2023年7月26日 |
股息 | 2022年7月15日 | HK$0.1758Annual | 2022年7月18日 | 2022年8月5日 |
除息 2026年7月10日
HK$0.1725
Annual
2026年7月13日登记 · 支付日 2026年7月31日
除息 2025年6月27日
HK$0.2731
Semi-Annual
2025年6月30日登记 · 支付日 2025年7月18日
除息 2024年9月4日
HK$0.0273
Semi-Annual
2024年9月5日登记 · 支付日 2024年9月27日
除息 2024年7月10日
HK$0.2741
Semi-Annual
2024年7月11日登记 · 支付日 2024年7月30日
除息 2023年7月7日
HK$0.2189
Annual
2023年7月10日登记 · 支付日 2023年7月26日
除息 2022年7月15日
HK$0.1758
Annual
2022年7月18日登记 · 支付日 2022年8月5日
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P Emerging Markets Small Cap ETFEWX23.7万0.04%6.74亿 USD0.65%US$70.93-0.95%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM16.12万0.00%97.34亿 USD0.39%US$39.58-1.54%
Dimensional - Emerging Core Equity Market ETFDFAE13.91万0.00%101.96亿 USD0.29%US$39.02-1.69%
Dimensional World ex U.S. Core Equity 2 ETFDFAX10.3万0.00%123.72亿 USD0.28%US$36.80-0.76%
Dimensional - Emerging Markets Value ETFDFEV5.18万0.00%22.02亿 USD0.46%US$42.16-1.47%State Street SPDR S&P Emerging Markets Small Cap ETFEWXDimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional - Emerging Core Equity Market ETFDFAEDimensional World ex U.S. Core Equity 2 ETFDFAXDimensional - Emerging Markets Value ETFDFEVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
